ICAM1 and neoplasm: Because LFA-1 is the principal canonical ligand for ICAM-1, in the second set of experimental conditions we blocked CD11a subunit of LFA-1 in the tumor cells with specific antibodies before co-culturing them with LSECs (Fig. 2B).